# Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）

> **NCT03855384** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 334 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
- **DRUG:** placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)

## Key facts

- **NCT ID:** NCT03855384
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-11
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-05-30
- **Target enrollment:** 334 (ESTIMATED)
- **Last updated:** 2019-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03855384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03855384, "Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03855384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*